 Hydrazines
"Hydrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D006834
|
| MeSH Number(s) |
D02.442
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazines".
Below are MeSH descriptors whose meaning is more specific than "Hydrazines".
This graph shows the total number of publications written about "Hydrazines" by people in UAMS Profiles by year, and whether "Hydrazines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 2 | 1 | 3 | | 2019 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2004 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 | | 1988 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydrazines" by people in Profiles over the past ten years.
-
Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, Deraedt W, Yeh TM, Banerjee A, Yalniz F, Nesheiwat T, Van Sanden S, Diels J, Valluri S, Usmani SZ, Berdeja JG, Jagannath S, Martin T. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):690-701.
-
Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor?+?dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021 10; 62(10):2482-2491.
-
Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 01; 96(1):E5-E8.
-
Tremblay G, Dolph M, Roy AN, Said Q, Forsythe A. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Clin Ther. 2020 05; 42(5):860-872.e8.
-
Forsythe A, Schneider J, Pham T, Bhor M, Said Q, Allepuz A, Socorro O Portella MD, Kwon CS, Roy AN. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. J Comp Eff Res. 2020 05; 9(7):447-457.
-
Kumari M, Purohit MP, Pahuja R, Patnaik S, Shukla Y, Kumar P, Gupta KC. Pro-inflammatory macrophage polarization enhances the anti-cancer efficacy of self-assembled galactomannan nanoparticles entrapped with hydrazinocurcumin. Drug Deliv Transl Res. 2019 12; 9(6):1159-1188.
-
Cai B, Said Q, Li X, Li FY, Arcona S. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag. J Med Econ. 2020 Mar; 23(3):243-251.
-
Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13.
-
Ujjwal RR, Purohit MP, Patnaik S, Ojha U. General Reagent Free Route to pH Responsive Polyacryloyl Hydrazide Capped Metal Nanogels for Synergistic Anticancer Therapeutics. ACS Appl Mater Interfaces. 2015 Jun 03; 7(21):11497-507.
-
Bharate JB, Abbat S, Sharma R, Bharatam PV, Vishwakarma RA, Bharate SB. Cobalt(II) catalyzed C(sp)-H bond functionalization of alkynes with phenyl hydrazines: facile access to diaryl 1,2-diketones. Org Biomol Chem. 2015 May 14; 13(18):5235-42.
-
Wang Y, Frett B, McConnell N, Li HY. Metal-free, efficient hydrazination of imidazo[1,2-a]pyridine with diethyl azodicarboxylate in neutral media. Org Biomol Chem. 2015 Mar 14; 13(10):2958-64.
-
Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leuk Lymphoma. 2014 Dec; 55(12):2901-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|